A San Francisco startup with personnel ties to Neuralink temporarily implanted a brain-computer interface in three patients undergoing brain tumor resection surgery at Royal Melbourne Hospital in Australia, per a WIRED report by Emily Mullin published 23 June 2026. The implant was in place for roughly 30 minutes during each surgery and then removed. The procedures were the first-in-human safety check for Coherence Neuro’s electroceutical platform, which is designed to sense the unique electrical signals of brain tumors and deliver mild electrical stimulation to prevent their growth. The patients consented to the implant placement prior to their tumor resection surgery. The work is the foundation for a chronic-implant trial in glioblastoma patients that Coherence plans to begin in 2027.

What Coherence Neuro is building, and what makes it different from Optune

Coherence Neuro was founded in 2022 in Cambridge, United Kingdom, as Opto Biosystems Limited by Ben Woodington and Elise Jenkins, both PhDs from the University of Cambridge’s Bioelectronics Lab. The company is now San Francisco-headquartered with United Kingdom and Australian operations. It closed a $10 million seed round in November 2025, co-led by Artesian and Topology Ventures, with participation from Blackbird Ventures, Possible Ventures, XEIA and Jumpspace among others. The Australian operating subsidiary, Coherence Neuro Australia Pty Limited, is the sponsor of the first-in-human study registered on ClinicalTrials.gov under NCT07465796.

The Coherence device is built around an implant that sits in the skull and has 16 extending threads that reach into the brain tissue. The thread-based architecture is closer in form factor to Neuralink’s N1 implant than to the surface or endovascular electrode arrays of other BCI competitors. Coherence’s commercial positioning is not BCI for movement or speech restoration. It is BCI for brain-cancer monitoring and electrical-stimulation therapy, with the implant placed during the patient’s brain tumor resection surgery and intended to remain in place after the tumor is removed.

The closest approved comparison in the brain-cancer device category is Optune, made by Novocure. Optune is a wearable device first approved by the FDA in 2011 for recurrent glioblastoma, with the newly-diagnosed indication added in 2015. The Optune Pax variant received FDA approval in February 2026 for locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel. The Optune device attaches to the scalp or abdomen with adhesive patches and improves survival by several months when worn for most of the day. Patients on Optune shave their heads and carry a battery in a backpack or on a hip belt. Coherence’s pitch is that an implanted device with continuous monitoring and customized stimulation can deliver the therapeutic effect without the shaved head, the battery backpack, or the visible signal of cancer treatment.

The Neuralink personnel ties

Matthew MacDougall, Neuralink’s head neurosurgeon, is named in the WIRED article as both an adviser to and an investor in Coherence Neuro. Rory Murphy, a neurosurgeon at the Barrow Neurological Institute in Arizona and an investigator on one of Neuralink’s clinical trials, is slated to be involved in future Coherence trials. Two senior Neuralink-affiliated neurosurgeons formally attached to a competing implantable-BCI venture is a structural signal about how the implantable-BCI clinical network operates: the surgeon community for high-channel-count brain implants is small, and the same names cycle across multiple companies’ clinical and advisory rosters.

First US clinical sites for a permanent-implant Coherence trial will likely route through neurosurgical centres that already operate Neuralink or other intracortical BCI programmes. The shared infrastructure for high-channel-count implantable devices, including the surgical robotics and the chronic patient management protocols, is concentrated in a small number of US centres. Coherence’s Neuralink-adjacent founding investor stack and named future-trial investigator place the company on the same clinical infrastructure rails.

The science of treating brain tumors with electrical stimulation

The premise of Coherence’s device is grounded in 2019 Stanford research showing that high-grade gliomas drive their own growth by forming synapses with healthy neurons. In that study, a seizure drug interrupted electrical signals to tumors and slowed their growth in mice. Separate research has shown that low-intensity electricity disrupts cancer cell division in brain tumors. These two pillars produce the therapeutic hypothesis Coherence is testing in humans: an implanted device that monitors the tumor’s electrical signature continuously and applies targeted stimulation to suppress tumor activity between or alongside standard-of-care treatments.

The clinical use case Coherence is pursuing is glioblastoma recurrence. Glioblastoma is the most lethal common brain cancer. Most patients live 15 to 18 months after diagnosis, with a five-year survival rate of under 10 per cent. Current standard surveillance is an MRI every two to three months between drug regimens. Ben Woodington, Coherence Neuro’s CEO, told WIRED that the MRI interval is not frequent enough: brain tumors can become more aggressive suddenly, and clinicians lack visibility into what happens between scans. Coherence’s pitch is that a continuous-monitoring implant can flag rapid tumor growth in time for the clinical team to intervene with surgery before the next scheduled MRI would have caught it.

What’s next, and what the trial registry says about today’s status

The intraoperative safety check at Royal Melbourne Hospital is registered as NCT07465796, sponsored by Coherence Neuro Australia Pty Limited, recruiting from 22 May 2026 with an estimated completion date of September 2026. The trial’s registered title is “A First-in-Human Study of the CIPHER System During Brain Surgery for Newly Diagnosed Glioma,” with the device named CIPHER on the registry. Coherence markets the chronic platform under the name SOMA. The relationship between CIPHER (intraoperative prototype) and SOMA (chronic implant) is not publicly clarified, and the registered trial is for short-duration intraoperative use during tumor resection, not for chronic implantation.

The chronic-implant trial that will test the actual product hypothesis is the 2027 study Coherence has flagged to WIRED. The 2027 trial is what the company needs to clear in order to convert the platform from intraoperative safety data into a real-world recurrence-monitoring and tumor-suppression device.

Where this sits on the BCI commercial map

The Coherence Neuro programme is a different commercial track from the BCI cohort that has been most visible in 2026 reporting. Neuralink, Synchron, Paradromics, Precision Neuroscience and Neuracle are scaling implantable BCIs for movement and speech restoration, mostly in spinal cord injury and ALS populations. Coherence is the first publicly disclosed BCI venture purpose-built for brain cancer monitoring and therapy. The category gap matters for two reasons. First, the regulatory pathway for an oncology BCI device is structurally different from the FDA Breakthrough or NMPA pathways the motor-restoration cohort has been using. Second, the patient population is larger and the willingness-to-pay calculation is different. A glioblastoma patient with an 18-month median prognosis has a different cost-benefit frame for an implanted device than an ALS patient with a multi-decade life expectancy in a paralysed state.

The Neuralink-adjacent personnel network and the thread-based architecture place Coherence inside the same implantable-BCI commercial corridor, even though the clinical application is on the opposite end of the device-category spectrum. The corridor produces shared surgical robotics suppliers, shared neurosurgical training infrastructure, and shared regulatory-strategy expertise. Coherence’s 2027 trial is the first commercial test of whether that corridor can carry a non-motor, non-speech application through to real-world deployment.

Two adjacent device-based brain-cancer programmes sit in different mechanistic lanes. Cahira Technologies, a Massachusetts Institute of Technology Sarkar laboratory spinout, is developing a brain-implant platform targeting cancer and Alzheimer’s, currently at mouse-stage. A 2023 Brigham and Women’s Hospital intracranial microdevice study led by Pierpaolo Peruzzi and Oliver Jonas placed drug-screening devices in six glioma patients and reported in Science Translational Medicine. Neither operates on Coherence’s electrical-stimulation premise.

The 2027 permanent-implant trial is the next material milestone. If Coherence enrols and produces interim safety and tumor-modulation data within twelve to eighteen months of trial start, the company becomes a commercially relevant BCI platform in a clinical category the rest of the implantable-BCI cohort is not addressing. If the 2027 trial slips or produces ambiguous data, Coherence reverts to a research-stage Neuralink-adjacent venture rather than a commercial test case. Today’s WIRED reporting is the first dated, named primary milestone the company has produced.

Sources

• 3 People Have Gotten Cancer-Detecting Implants in Their Brains (WIRED, Emily Mullin, 23 June 2026)
• ClinicalTrials.gov NCT07465796 — First-in-Human Study of the CIPHER System During Brain Surgery for Newly Diagnosed Glioma
• Coherence Neuro company website
• Coherence Neuro raises $10M seed round (MassDevice, Sean Whooley, 5 November 2025)
• Implantable-Device.com profile of Coherence Neuro electroceutical (David Prutchi, 17 January 2026)
• XEIA Ventures investment memo on Coherence Neuro
• Optune (Novocure) device information
• Brigham and Women’s Hospital intracranial microdevice study (NIH Research Matters, 2023)
• Cahira Technologies / MIT Sarkar lab implantable brain device (MIT News, November 2025)